查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571995

聚乙二醇化蛋白质的全球市场

PEGylated Proteins
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球聚乙二醇化蛋白质市场预计将达到 20 亿美元

聚乙二醇化蛋白质的全球市场预计 2023 年为 11 亿美元，预计到 2030 年将达到 20 亿美元，2023-2030 年分析期间复合年增长率为 9.1%。聚乙二醇化蛋白质消耗品是本报告分析的细分市场之一，预计复合年增长率为 8.5%，到分析期结束时将达到 13 亿美元。分析期间，聚乙二醇化蛋白质服务产业的复合年增长率预计为 10.5%。

美国市场预估为2.949亿美元，中国预期复合年增长率为8.5%

预计 2023 年美国聚乙二醇化蛋白市场规模将达 2.949 亿美元。中国作为全球第二大经济体，预计2030年市场规模将达3.063亿美元，2023-2030年分析期间复合年增长率为8.5%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 7.8% 和 8.0%。在欧洲，德国预计复合年增长率为 7.2%。

全球聚乙二醇化蛋白质市场—主要趋势与驱动因素总结

科技进步如何推动聚乙二醇化蛋白质的发展？

聚乙二醇化蛋白质将聚乙二醇 (PEG) 链附着在蛋白质上，由于其能够改善生技药品的药物动力学和治疗功效，因此在生物製药开发中变得越来越重要。蛋白质工程和聚乙二醇化技术的进步使得蛋白质的修饰变得更加精确和可控，从而提高了治疗性蛋白质的稳定性、降低了免疫抗原性并增加了溶解度。这些创新使聚乙二醇化蛋白质能够在血液中循环更长时间，从而减少给药频率并提高患者的依从性。最近的趋势包括位点特异性聚乙二醇化技术的创建。这确保了 PEG 分子指定在蛋白质上并保持蛋白质的生物活性。此外，聚乙二醇化化学的进步提高了聚乙二醇化酶、胜胜肽和抗体的功效，使它们在肿瘤学、免疫学和血液学等各种治疗领域中具有更广泛的用途。这些突破不仅推动了药物开发，也改善了接受生技药品治疗的患者的治疗结果。

为什么生物製药对聚乙二醇化蛋白质的需求量很大？

生物製药领域对聚乙二醇化蛋白质的需求正在迅速增加，这主要是因为它们能够克服与基于蛋白质的治疗相关的许多挑战。聚乙二醇化的主要优点之一是它能够降低蛋白质的免疫抗原性，使它们不太可能被免疫系统识别和破坏。这项特性在生物製药开发中特别有价值，因为它提高了蛋白质疗法的安全性和有效性。聚乙二醇化蛋白质也更能抵抗体内酵素的降解，且半衰期显着更长，这可以减少给药频率并提高患者的依从性。这对于需要长期治疗的慢性疾病尤其有益。此外，聚乙二醇化蛋白质在标靶药物传递方面也显示出巨大的潜力，可以将治疗性蛋白质精确地递送到特定的组织和细胞，同时最大限度地减少脱靶效应。随着对长效、有效和患者友好的生技药品的需求不断增长，聚乙二醇化蛋白质正在成为下一代治疗的重要组成部分。

医疗保健和监管标准的变化如何影响聚乙二醇化蛋白质市场？

医疗保健领域不断变化的趋势，特别是对个人化医疗和标靶治疗的日益重视，对聚乙二醇化蛋白质的采用产生了重大影响。随着生物製药成为主流治疗药物，对更安全、更有效且针对个别患者需求的治疗的需求不断增长。聚乙二醇化蛋白质符合个人化医疗的原则，具有可客製化的药物动力学和减少的副作用。此外，监管环境在塑造聚乙二醇化蛋白质市场方面发挥重要作用。美国食品药物管理局(FDA) 和欧洲药品管理局 (EMA) 等监管机构专注于核准证明临床疗效又能降低免疫抗原性风险的生技药品，而聚乙二醇化这使其成为对开发商有吸引力的策略。生物相似药尤其是聚乙二醇化生物相似药的需求也在上升，为市场拓展提供了新的机会。随着医疗保健系统越来越重视基于价值的医学，聚乙二醇化蛋白质提供了一种创新的解决方案，可以满足对安全、有效和长效生技药品的需求。

推动聚乙二醇化蛋白质市场成长的因素有哪些？

聚乙二醇化蛋白质市场的成长受到多种因素的推动，例如技术进步、对生技药品的需求不断增加以及转向以患者为中心的护理模式的转变。主要驱动因素之一是癌症、自体免疫疾病和糖尿病等慢性疾病的盛行率不断上升，这些疾病需要长期使用蛋白质为基础的疗法进行治疗。聚乙二醇化蛋白质可延长半衰期并提高疗效，减少频繁给药的需要并提高患者的依从性。位点特异性聚乙二醇化和控制释放机制的技术进步也正在推动市场发展，以实现更精确的治疗结果。此外，生物製药产业对生物相似药开发的日益关注也推动了对聚乙二醇化蛋白质的需求。对生技药品和生物相似药开发的监管支持，加上医疗保健支出的增加，正在进一步推动市场成长。随着医疗保健提供者和製药公司寻求开发更有效和对患者友好的治疗方法，聚乙二醇化蛋白质有望在推进生物製药疗法方面发挥关键作用。

受访企业范例（共46家）

  • BIA Separations doo
  • Biomatrik Inc.
  • Celares GmbH
  • Creative PEGWorks
  • IRIS Biotech GmbH
  • Jenkem Technology Co., Ltd.
  • Thermo Fisher Scientific, Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他领域

第四章 比赛

简介目录
Product Code: MCP13899

Global PEGylated Proteins Market to Reach US$2.0 Billion by 2030

The global market for PEGylated Proteins estimated at US$1.1 Billion in the year 2023, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2023-2030. PEGylated Protein Consumables, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the PEGylated Protein Services segment is estimated at 10.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$294.9 Million While China is Forecast to Grow at 8.5% CAGR

The PEGylated Proteins market in the U.S. is estimated at US$294.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$306.3 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.8% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global PEGylated Proteins Market – Key Trends & Drivers Summarized

How Are Technological Advancements Enhancing the Development of PEGylated Proteins?

PEGylated proteins, which involve the attachment of polyethylene glycol (PEG) chains to proteins, have become increasingly important in biopharmaceutical development due to their ability to improve the pharmacokinetics and therapeutic efficacy of biologics. Advances in protein engineering and PEGylation technologies are enabling more precise and controlled modification of proteins, leading to improved stability, reduced immunogenicity, and enhanced solubility of therapeutic proteins. These technological innovations allow PEGylated proteins to have prolonged circulation times in the bloodstream, thereby reducing the frequency of dosing and improving patient compliance. Recent developments also include the creation of site-specific PEGylation techniques, which ensure that the PEG molecule attaches to a predetermined location on the protein, preserving the protein’s biological activity. Additionally, advances in PEGylation chemistry are improving the efficacy of PEGylated enzymes, peptides, and antibodies, making them more versatile and applicable across various therapeutic areas, including oncology, immunology, and hematology. These breakthroughs are not only advancing drug development but are also improving the therapeutic outcomes for patients undergoing treatment with biologics.

Why Are PEGylated Proteins in High Demand Across Biopharmaceuticals?

The demand for PEGylated proteins is rapidly increasing within the biopharmaceutical sector, primarily due to their ability to overcome many of the challenges associated with protein-based therapeutics. One of the key benefits of PEGylation is its ability to reduce the immunogenicity of proteins, making them less likely to be recognized and destroyed by the immune system. This property is particularly valuable in the development of biopharmaceuticals, as it enhances the safety and efficacy of protein therapeutics. PEGylated proteins are also more resistant to degradation by enzymes in the body, which significantly extends their half-life, allowing for reduced dosing frequencies and improved patient adherence. This is especially beneficial for chronic conditions that require long-term treatment. Furthermore, PEGylated proteins have shown considerable promise in targeted drug delivery, enabling precise delivery of therapeutic proteins to specific tissues or cells while minimizing off-target effects. As the demand for long-acting, effective, and patient-friendly biologics continues to grow, PEGylated proteins are emerging as a key component of next-generation therapies.

How Are Shifts in Healthcare and Regulatory Standards Impacting the PEGylated Proteins Market?

Shifting trends in healthcare, particularly the growing emphasis on personalized medicine and targeted therapies, are significantly influencing the adoption of PEGylated proteins. With the rise of biologics as a leading class of therapeutics, there is increasing demand for treatments that can be tailored to individual patient needs while offering enhanced safety and efficacy. PEGylated proteins, with their customizable pharmacokinetics and reduced side-effect profiles, align well with the principles of personalized medicine. Additionally, the regulatory landscape is playing a crucial role in shaping the PEGylated proteins market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are focusing on approving biologics that demonstrate both clinical efficacy and reduced immunogenic risks, making PEGylation an attractive strategy for drug developers. The demand for biosimilars, particularly PEGylated biosimilars, is also on the rise, providing new opportunities for market expansion. As healthcare systems increasingly prioritize value-based care, PEGylated proteins offer an innovative solution that aligns with the need for safe, effective, and long-acting biologics.

What Factors Are Driving Growth in the PEGylated Proteins Market?

The growth in the PEGylated proteins market is driven by several factors, including technological advancements, rising demand for biologics, and the shift toward patient-centric care models. One of the primary drivers is the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes, which require long-term treatment with protein-based therapies. PEGylated proteins offer extended half-lives and improved efficacy, reducing the need for frequent dosing and improving patient adherence. Technological advancements in site-specific PEGylation and controlled-release mechanisms are also propelling the market, enabling more precise therapeutic outcomes. Additionally, the biopharmaceutical industry's growing focus on developing biosimilars is driving demand for PEGylated proteins, as they offer a cost-effective alternative to branded biologics with comparable efficacy. Regulatory support for the development of biologics and biosimilars, coupled with increasing healthcare spending, is further boosting market growth. As healthcare providers and pharmaceutical companies seek to develop more effective and patient-friendly treatments, PEGylated proteins are poised to play a critical role in advancing biologic therapies.

Select Competitors (Total 46 Featured) -

  • BIA Separations d.o.o.
  • Biomatrik Inc.
  • Celares GmbH
  • Creative PEGWorks
  • IRIS Biotech GmbH
  • Jenkem Technology Co., Ltd.
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • PEGylated Proteins - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Biopharmaceuticals Drives Growth in the PEGylated Proteins Market
    • Technological Advancements in PEGylation Processes Enhance the Stability and Efficacy of Biologic Drugs
    • Increasing Use of PEGylated Proteins in Cancer Treatment Expands Opportunities in Oncology
    • Growing Adoption of PEGylated Therapeutics in Rare Disease Treatment Strengthens Market Growth
    • Rising Focus on Prolonging Drug Half-Life Drives Demand for PEGylated Proteins in Drug Delivery Systems
    • Advancements in Site-Specific PEGylation Techniques Enhance Precision and Effectiveness of Therapeutics
    • Growing Applications of PEGylated Proteins in Immunotherapy and Vaccines Expands Market Potential
    • Increased Use of PEGylated Enzymes in Metabolic Disorders Expands Opportunities in Enzyme Replacement Therapy
    • Rising Research and Development in Biotechnology Fuels Innovation in PEGylated Protein Therapeutics
    • Technological Integration of PEGylation with Monoclonal Antibodies Enhances Targeted Drug Delivery
    • Increasing Adoption of PEGylated Proteins in Chronic Disease Management Strengthens the Case for Long-Term Therapeutics
    • Growing Use of PEGylated Liposomes in Drug Formulations Expands Market for Advanced Drug Delivery Systems
    • Rising Focus on Reducing Immunogenicity in Protein Therapeutics Drives Growth in PEGylation Technologies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World PEGylated Proteins Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for PEGylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Interferons by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Erythropoietin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for mAbs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for mAbs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Recombinant Factor VIII by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Recombinant Factor VIII by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Protein Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Other Protein Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: USA 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: USA 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Canada 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Canada 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • JAPAN
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Japan 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Japan 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • CHINA
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: China 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: China 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • EUROPE
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe 7-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: Europe 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Europe 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • FRANCE
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: France 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: France 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • GERMANY
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Germany 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Germany 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Italy 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Italy 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • UNITED KINGDOM
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 77: UK 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 79: UK 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • ASIA-PACIFIC
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 95: Rest of World 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 97: Rest of World 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030

IV. COMPETITION